(ALCRB) Carbios - Ratings and Ratios
Enzymatic, Biodegradable, Biocatalysis, Recycling
Description: ALCRB Carbios
Carbios (ALCRB) is a French company operating in the Commodity Chemicals sub-industry, with a market capitalization of €138.83M. The stock has exhibited significant volatility, with a beta of 1.967, indicating its returns are nearly twice as sensitive to market fluctuations.
The companys financials reveal a challenging situation, with a negative Return on Equity (RoE) of -31.55%, suggesting substantial losses. The absence of a Price-to-Earnings (P/E) ratio, either current or forward, further indicates that Carbios is not generating profits. This scenario often characterizes companies in early stages of development or those undergoing significant restructuring.
From a technical standpoint, the stock price has been trending upwards, with the short-term (SMA20), medium-term (SMA50), and long-term (SMA200) moving averages at €8.72, €7.87, and €7.09, respectively, and the current price at €9.53. This suggests a potential bullish trend. The Average True Range (ATR) of 0.55, or 5.83% of the current price, indicates moderate volatility.
To evaluate the investment potential of ALCRB, key performance indicators (KPIs) such as revenue growth, cash flow generation, and the path to profitability are crucial. Economic drivers for Commodity Chemicals companies include raw material prices, demand for sustainable solutions, and regulatory environments. Given Carbios focus on enzymatic recycling of plastics, its success may be tied to the growing demand for eco-friendly technologies and government policies supporting circular economy practices.
Investors should closely monitor Carbios ability to scale its technology, achieve commercialization milestones, and manage its cash burn rate, as these factors will be critical in determining the companys future financial health and stock performance. A detailed analysis of the quarterly tax provision data could provide insights into the companys tax strategy and potential impacts on its cash flow and profitability.
ALCRB Stock Overview
| Market Cap in USD | 185m |
| Sub-Industry | Commodity Chemicals |
| IPO / Inception |
ALCRB Stock Ratings
| Growth Rating | -55.8% |
| Fundamental | 31.1% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -56.0% |
| Analyst Rating | - |
ALCRB Dividends
Currently no dividends paidALCRB Growth Ratios
| Growth Correlation 3m | 79.6% |
| Growth Correlation 12m | -7.1% |
| Growth Correlation 5y | -87% |
| CAGR 5y | -20.43% |
| CAGR/Max DD 3y | -0.24 |
| CAGR/Mean DD 3y | -0.49 |
| Sharpe Ratio 12m | -0.50 |
| Alpha | -63.35 |
| Beta | 0.782 |
| Volatility | 75.66% |
| Current Volume | 37.2k |
| Average Volume 20d | 56.6k |
| Stop Loss | 8.9 (-8.1%) |
| Signal | 0.51 |
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-60.3m TTM) > 0 and > 6% of Revenue (6% = 9600 TTM) |
| FCFTA -0.33 (>2.0%) and ΔFCFTA -16.78pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 41.6k% (prev 99.9k%; Δ -58.3kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.19 (>3.0%) and CFO -53.5m > Net Income -60.3m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 2.79 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (16.9m) change vs 12m ago NaN% (target <= -2.0% for YES) |
| Gross Margin -272.5% (prev 94.29%; Δ -366.8pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.05% (prev 0.02%; Δ 0.03pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -36.29 (EBITDA TTM -38.3m / Interest Expense TTM 1.30m) >= 6 (WARN >= 3) |
Altman Z'' -1.46
| (A) 0.24 = (Total Current Assets 103.6m - Total Current Liabilities 37.1m) / Total Assets 280.0m |
| (B) -0.30 = Retained Earnings (Balance) -84.3m / Total Assets 280.0m |
| (C) -0.16 = EBIT TTM -47.1m / Avg Total Assets 291.0m |
| (D) -0.90 = Book Value of Equity -72.5m / Total Liabilities 80.3m |
| Total Rating: -1.46 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 31.13
| 1. Piotroski 0.50pt = -4.50 |
| 2. FCF Yield -87.00% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.18 = 2.48 |
| 5. Debt/Ebitda -0.93 = -2.50 |
| 6. ROIC - WACC data missing |
| 7. RoE -31.55% = -2.50 |
| 8. Rev. Trend -61.94% = -3.10 |
| 9. Rev. CAGR -61.51% = -2.50 |
| 10. EPS Trend -50.19% = -1.25 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of ALCRB shares?
Over the past week, the price has changed by +9.57%, over one month by +1.57%, over three months by +29.26% and over the past year by -47.70%.
Is Carbios a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ALCRB is around 8.18 EUR . This means that ALCRB is currently overvalued and has a potential downside of -15.5%.
Is ALCRB a buy, sell or hold?
What are the forecasts/targets for the ALCRB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 26 | 168.6% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 9.2 | -5.4% |
ALCRB Fundamental Data Overview
Market Cap EUR = 157.6m (157.6m EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 86.7m EUR (last quarter)
P/S = 1158.881
P/B = 0.794
Beta = 1.909
Revenue TTM = 160.0k EUR
EBIT TTM = -47.1m EUR
EBITDA TTM = -38.3m EUR
Long Term Debt = 31.2m EUR (from longTermDebt, last quarter)
Short Term Debt = 4.57m EUR (from shortTermDebt, last quarter)
Debt = 35.7m EUR (Calculated: Short Term 4.57m + Long Term 31.2m)
Net Debt = -44.1m EUR (from netDebt column, last quarter)
Enterprise Value = 106.6m EUR (157.6m + Debt 35.7m - CCE 86.7m)
Interest Coverage Ratio = -36.29 (Ebit TTM -47.1m / Interest Expense TTM 1.30m)
FCF Yield = -87.00% (FCF TTM -92.8m / Enterprise Value 106.6m)
FCF Margin = -58.0k% (FCF TTM -92.8m / Revenue TTM 160.0k)
Net Margin = -37.7k% (Net Income TTM -60.3m / Revenue TTM 160.0k)
Gross Margin = -272.5% ((Revenue TTM 160.0k - Cost of Revenue TTM 596.0k) / Revenue TTM)
Tobins Q-Ratio = -1.47 (set to none) (Enterprise Value 106.6m / Book Value Of Equity -72.5m)
Interest Expense / Debt = 3.63% (Interest Expense 1.30m / Debt 35.7m)
Taxrate = unknown
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 2.79 (Total Current Assets 103.6m / Total Current Liabilities 37.1m)
Debt / Equity = 0.18 (Debt 35.7m / last Quarter total Stockholder Equity 199.7m)
Debt / EBITDA = -0.93 (Net Debt -44.1m / EBITDA -38.3m)
Debt / FCF = -0.39 (Debt 35.7m / FCF TTM -92.8m)
Total Stockholder Equity = 191.2m (last 4 quarters mean)
RoA = -21.55% (Net Income -60.3m, Total Assets 280.0m )
RoE = -31.55% (Net Income TTM -60.3m / Total Stockholder Equity 191.2m)
RoCE = -21.16% (Ebit -47.1m / (Equity 191.2m + L.T.Debt 31.2m))
RoIC = unknown (NOPAT none, Invested Capital 228.7m, Ebit -47.1m)
WACC = unknown (E(157.6m)/V(193.3m) * Re(8.90%)) + (D(35.7m)/V(193.3m) * Rd(3.63%) * (1-Tc(none)))
Shares Correlation 3-Years: 80.92 | Cagr: 7.63%
Discount Rate = 8.90% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -92.8m)
Revenue Correlation: -61.94 | Revenue CAGR: -61.51%
Rev Growth-of-Growth: 288.6
EPS Correlation: -50.19 | EPS CAGR: 0.0%
EPS Growth-of-Growth: -20.70